

SARDA PROTEINS LTD.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Date: 29th October, 2021

(BY BSE LISTING CENTRE)

Sub: Outcome of the Board Meeting held on Friday, 29th October, 2021 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir/Ma'am,

The Board of Directors of the Company in their meeting held on Friday, 29th October, 2021 at the corporate office of the company situated at Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan) which commenced at 12:00 P.M. and concluded at 2:20 P.M. *inter-alia*, transacted the following business:

1. Approved the Un-audited Financial Results of the company for the quarter and half year ended on 30th September, 2021 along with Statement of Assets and Liabilities as on that date and Cash Flow Statement for the half year ended on 30th September, 2021 (Copy of the same Enclosed herewith).

Further, the extract of the Un-audited Financial Results would also be published in the newspapers in compliance with Regulation 47 of "Listing Regulations".

2. Took on record the Limited Review Report on the Un-Audited Financial Results for the quarter and half year ended on 30th September, 2021. (Copy of the same Enclosed herewith).


TRADING WINDOW:

Further in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company's code of conduct for Prohibition of Insider Trading the "Trading Window" for trading in the shares of the Company will open from 01st November, 2021 for all Designated Persons, their immediate relative and other connected person(s).

You are requested to kindly take the same on record.

Thanking you,
Yours faithfully,

FOR SARDA PROTEINS LTD
For SARDA PROTEINS LTD


Company Secretary

AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M. NO.: A29371

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)

Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)


Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com

SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, Email: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2021

S. No.	Particulars	Quarter ended			Half Year ended		Rs.in Lakhs
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	Year ended
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I.	Revenue from Operations	74.58	69.76	1,038.14	144.34	1,038.14	1,135.99
II.	Other Income	2.54	2.10	2.06	4.64	4.07	8.39
III.	Total Income (I+II)	77.12	71.86	1,040.20	148.98	1,042.21	1,144.38
IV.	Expenses:						
	Cost of Material Consumed		-	-	-	-	-
	Purchase of Stock -in- Trade	73.58	69.75	1,000.30	143.33	1,000.30	1,098.06
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)		-	-	-	-	-
	Employee Benefit Expenses	2.87	3.68	2.62	6.55	5.46	12.16
	Finance Cost	0.02	-	0.01	0.02	0.01	0.14
	Depreciation and Amortisation Expenses	0.02	0.02	0.08	0.04	0.16	0.05
	Other expenses	3.02	-	20.11	3.02	23.30	27.84
	Total Expenses (IV)	79.51	73.45	1,023.12	152.96	1,029.23	1,138.25
V.	Profit/(Loss) before Exceptional and Extraordinary Items*and Tax (III-IV)	(2.39)	(1.59)	17.08	(3.98)	12.98	6.13
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(Loss) before Tax (V-VI)	(2.39)	(1.59)	17.08	(3.98)	12.98	6.13
VIII.	Tax Expense:						
	(1) Current Tax	-	-	-	-	-	0.95
	(2) Deferred Tax	-	-	-	-	-	7.20
IX.	Profit/(Loss) for the period from Continuing Operations (VII-VIII)	(2.39)	(1.59)	17.08	(3.98)	12.98	(2.02)
X.	Profit/(Loss) from Discontinued Operations	-	-	-	-	-	-
XI.	Tax Expenses of Discontinued Operations	-	-	-	-	-	-
XII.	Profit/(Loss) from Discontinued Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/(Loss) for the Period (IX+XII)	(2.39)	(1.59)	17.08	(3.98)	12.98	(2.02)
XIV.	Other Comprehensive Income						
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
XV.	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and other Comprehensive Income for the period)	(2.39)	(1.59)	17.08	(3.98)	12.98	(2.02)
XVI.	Paid Up Equity Share Capital, Equity Shares Of Face Value Rs. 10 each	172.59	172.59	172.59	172.59	172.59	172.59
XVII.	Earnings per Equity Share						
	(1) Basic	(0.14)	(0.09)	0.99	(0.23)	0.75	(0.12)
	(2) Diluted	(0.14)	(0.09)	0.99	(0.23)	0.75	(0.12)





SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, EMail: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER 2021

Particulars		Rs in Lakhs		
		Six Months ended		Year ended
		30.09.2021 Un-Audited	30.09.2020 Un-Audited	31.03.2021 Audited
A. ASSETS				
1. Non-Current Assets				
a) Property, Plant and Equipment		0.50	0.43	0.54
b) Capital work in progress		-	-	-
c) Investment Property		-	-	-
d) Goodwill		-	-	-
e) Other Intangible Assets		-	-	-
f) Intangible Assets under Development		-	-	-
g) Biological Assets other than bearer plants		-	-	-
h) Financial Assets		-	-	-
i) Investments		-	-	-
ii) Trade Receivables		0.13	0.13	0.13
iii) Loans		-	-	-
i) Deferred Tax Assets (net)		-	0.01	-
j) Other non-current Assets		22.62	29.82	22.62
2. Current Assets		-	0.21	-
a) Inventories		-	-	-
b) Financial Assets		-	-	-
i) Investments		-	-	-
ii) Trade Receivables		-	-	-
iii) Cash and Cash Equivalents		82.87	97.11	77.00
iv) Bank Balances and other than (iii) above		0.03	0.03	13.39
v) Loans		2.03	4.66	-
v) Others		97.36	95.24	99.62
c) Current Tax Assets (net)		-	-	-
d) Other Current Assets		-	-	-
Total Assets		205.54	227.64	213.30
B. EQUITY AND LIABILITIES				
1. Equity				
a) Equity Share Capital		250.45	250.45	250.45
b) Other Equity		(48.56)	(27.54)	(42.55)
2. Liabilities				
Non current Liabilities				
a) Financial Liabilities				
i) Borrowings		-	-	-
ii) Trade Payables		-	-	-
A) Total Outstanding dues to MSEs		-	-	-
B) Total Outstanding dues to Creditors other than MSEs		-	-	-
iii) Other Financial Liabilities		-	-	-
b) Provisions		-	-	-
c) Deferred Tax Liabilities (net)		1.42	1.01	2.09
d) Other Non Current Liabilities		-	-	-
Current Liabilities		-	-	-
a) Financial Liabilities				
i) Borrowings		-	-	-
ii) Trade Payables		-	-	-
A) Total Outstanding dues to MSEs		-	-	-
B) Total Outstanding dues to Creditors other than MSEs		-	-	-
iii) Other Financial Liabilities		0.08	0.03	-
b) Other Current Liabilities		-	-	-
c) Provisions		(1.66)	1.66	3.31
d) Current Tax Liabilities (net)		2.09	2.31	-
Total Equity and Liabilities		205.54	227.64	213.30



SARDA PROTEINS LTD

Reg Off: B-536-537, Matsya Industrial Area, Alwar-301030 (Rajasthan)
Phone: +91 7737822222, Email: sardaproteins@yahoo.com, website: www.sardaproteins.com
CIN: L15142RJ1991PLC006353

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2021


Particulars		Six Months ended		Rs in Lakhs
		30.09.2021	30.09.2020	Year ended
		Un-Audited	Un-Audited	Audited
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit before Tax and Extraordinary Items		(3.98)	12.98	6.13
A. ADJUSTMENT FOR				
Depreciation		0.04	0.16	0.05
Interest Received		(4.64)	(4.02)	(8.39)
Profit on Sale of Investment		-	-	-
Dividend		-	-	-
(Profit) /Loss on sale of Fixed Assets		-	-	-
Interest Paid		-	0.01	0.13
Operating Profit/(Loss) before Working Capital Charges		(8.58)	9.13	(2.08)
ADJUSTMENT FOR:				
Trade and other Receivables		(3.61)	(13.66)	(2.48)
Inventories		-	-	-
Trade & other Payables		(1.78)	(0.48)	0.19
Other Non Current Assets		(2.00)	-	0.22
Cash Generated from Operations		(15.97)	(5.01)	(4.15)
Direct Taxes Paid		-	-	0.95
Net Cash from Operating Activities		(15.97)	(5.01)	(5.10)
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital Expenditure		-	-	-
Sale of Fixed Assets		-	-	-
Profit/ (Loss) on sale of Fixed Assets		-	-	-
Profit on sale of Investment		-	-	-
Sale of Investment		-	-	-
Interest Received		4.64	4.02	8.39
Dividend Received		-	-	-
Net Cash Received from Investing Activities		4.64	4.02	8.39
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Long Term Borrowings		-	(4.55)	-
Proceeds from Short Term Borrowings		-	-	-
Interest Paid		-	(0.01)	(0.13)
Net Cash Inflow/ (Outflow) from Financing Activities		-	(4.56)	(0.13)
Net Cash Increase/(Decrease) in Cash and Cash Equivalants (A+B+C)		(11.33)	(5.55)	3.16
Cash & Cash Equivalants (Opening)		13.39	10.24	10.23
Cash & Cash Equivalants (Closing)		2.06	4.69	13.39

Notes:


- The above results were approved by Audit Committee and Board of Directors in their meeting held on 29th October 2021.
- Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
- Segment Results as per AS is not applicable as dealing in only one segment i.e. " Agro Products".
- No Investor Complaints were received during the quarter ended 30-Sep-2021 nor any pending as on 01-Oct-2021.
- Figures for the previous period have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

on behalf of the Board
Sarda Proteins Ltd

Place: Jaipur
Date : 29-Oct-2021



Deepak Data (DIN: 01672415)
Managing Director





Khetawat Agarwal & Co.
Chartered Accountants

Limited Review Report
Unaudited Standalone Quarterly and Half Year Results

To
The Board of Directors
Sarda Proteins Ltd


We have reviewed the accompanying statement of unaudited financial results of **SARDA PROTEINS LTD** for the Quarter and Half Year ended on 30th September, 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For Khetawat Agarwal & Co.
Chartered Accountants

FRN: 003960C


M.L. Agarwal
Partner

M. No.: 072854

UDIN : 21072854AAAACT2323



Place : Jaipur

Date : 29.10.2021

Office : 103, 1st Floor, City Center, Ashok Circle, Alwar-301001 (Rajasthan)

Phone : Office 0144 - 2340924, 7014347644

Mobile : 9414215353 (ML Agarwal)

E-mail : khetawatagarwal21@gmail.com